NFKB1 and diffuse large B-cell lymphoma: Similarly, in some DLBCL subtypes that exhibit continuous NF‐κB activation, BTK inhibitor has also been shown to have therapeutic value as a key molecule for BCR to activate the NF‐κB pathway.421